Drug Search Results
More Filters [+]

FRM-6308

Alternative Names: frm-6308, frm 6308, frm6308, evp-6308, evp6308, evp 6308
Latest Update: 2015-01-12
Latest Update Note: Clinical Trial Update

Product Description

FRM-6308 (FORUM Pharmaceuticals, Inc.) is a novel, potent and highly selective PDE10A inhibitor that has also demonstrated antipsychotic efficacy in rodent models (conditioned avoidance responding, stimulant-induced locomotor activity and prepulse inhibition tests). FRM-6308 was active at doses that did not produce decreases in spontaneuous locomotor activity or catalepsy (unpublished data). (Sourced from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5028314/)

Mechanisms of Action: PDE10 Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: N/A

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: FORUM
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for FRM-6308

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 1: Healthy Volunteers|Schizophrenia

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

EVP-6308-003

P1

Completed

Schizophrenia

2014-12-01

EVP-6308-002

P1

Completed

Healthy Volunteers

2014-06-01

Recent News Events

Date

Type

Title